Allergy Therapeutics logo

AGY - Allergy Therapeutics Share Price

25p 2.3  9.9%

Last Trade - 09/04/21

Small Cap
Market Cap ÂŁ160.2m
Enterprise Value ÂŁ123.9m
Revenue ÂŁ81.8m
Position in Universe 901st / 1817
Unlock AGY Revenue
Relative Strength (%)
1m +3.17%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High 0.000
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
43.2 48.5 64.1 68.3 73.7 78.2 83.0 88.1 +12.6%
-86.0 +102.3
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, AllergyTherapeutics plc revenues increased 7% to ÂŁ54M. Net incomedecreased 2% to ÂŁ14.9M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Net income was offset byAdministration expenses increase of 18% to ÂŁ9.6M (expense),Finance income decrease of 76% to ÂŁ36K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AGY
Graphical History


AGY Revenue Unlock AGY Revenue

Net Income

AGY Net Income Unlock AGY Revenue

Normalised EPS

AGY Normalised EPS Unlock AGY Revenue

PE Ratio Range

AGY PE Ratio Range Unlock AGY Revenue

Dividend Yield Range

AGY Dividend Yield Range Unlock AGY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AGY EPS Forecasts Unlock AGY Revenue
Profile Summary

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated June 1, 2004
Public Since October 11, 2004
No. of Shareholders: n/a
No. of Employees: 571
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 640,940,533
Free Float (0.0%)
Eligible for
AGY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AGY
Upcoming Events for AGY
Frequently Asked Questions for Allergy Therapeutics
What is the Allergy Therapeutics share price?

As of 09/04/21, shares in Allergy Therapeutics are trading at 25p, giving the company a market capitalisation of ÂŁ160.2m. This share price information is delayed by 15 minutes.

How has the Allergy Therapeutics share price performed this year?

Shares in Allergy Therapeutics are currently trading at 25p and the price has moved by 0.144k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Allergy Therapeutics price has moved by 97.05% over the past year.

What are the analyst and broker recommendations for Allergy Therapeutics?

Of the analysts with advisory recommendations for Allergy Therapeutics, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Allergy Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Allergy Therapeutics next release its financial results?

Allergy Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Allergy Therapeutics dividend yield?

Allergy Therapeutics does not currently pay a dividend.

Does Allergy Therapeutics pay a dividend?

Allergy Therapeutics does not currently pay a dividend.

When does Allergy Therapeutics next pay dividends?

Allergy Therapeutics does not currently pay a dividend.

How do I buy Allergy Therapeutics shares?

To buy shares in Allergy Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Allergy Therapeutics?

Shares in Allergy Therapeutics are currently trading at 25p, giving the company a market capitalisation of ÂŁ160.2m.

Where are Allergy Therapeutics shares listed? Where are Allergy Therapeutics shares listed?

Here are the trading details for Allergy Therapeutics:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: AGY
What kind of share is Allergy Therapeutics?

Based on an overall assessment of its quality, value and momentum, Allergy Therapeutics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Allergy Therapeutics share price forecast 2021?

Shares in Allergy Therapeutics are currently priced at 25p. At that level they are trading at 64.24% discount to the analyst consensus target price of 69.91.

Analysts covering Allergy Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.00808 for the next financial year.

How can I tell whether the Allergy Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allergy Therapeutics. Over the past six months, the relative strength of its shares against the market has been 23.47%. At the current price of 25p, shares in Allergy Therapeutics are trading at 49.02% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Allergy Therapeutics PE Ratio?

The Allergy Therapeutics PE ratio based on its reported earnings over the past 12 months is 20.41. The shares are currently trading at 25p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Allergy Therapeutics?

Allergy Therapeutics's management team is headed by:

Stephen Smith - NID
Manuel Llobet - CEO
Peter Jensen - NEC
Nicolas Wykeman - CFO
Babatunde Otulana - NID
Scott Leinenweber - NID
Mary Tavener - NID
Who are the major shareholders of Allergy Therapeutics?

Here are the top five shareholders of Allergy Therapeutics based on the size of their shareholding:

Weinstein Jr (Alejandro Esteban) Individual Investor
Percentage owned: 37.54% (240.6m shares)
Southern Fox Investments, Ltd. Corporation
Percentage owned: 22.42% (143.7m shares)
Skygem Acquisition, Ltd. Corporation
Percentage owned: 20.07% (128.6m shares)
INVESCO Asset Management Limited Investment Advisor/Hedge Fund
Percentage owned: 4.74% (30.4m shares)
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund
Percentage owned: 4.74% (30.4m shares)
Similar to AGY
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.